Pamela M Rist1, Monik C Jiménez2, Kathryn M Rexrode2. 1. From the Division of Preventive Medicine (P.M.R, M.C.J., K.M.R.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; and Department of Epidemiology (P.M.R.), Harvard T.H. Chan School of Public Health, Boston, MA. prist@mail.harvard.edu. 2. From the Division of Preventive Medicine (P.M.R, M.C.J., K.M.R.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; and Department of Epidemiology (P.M.R.), Harvard T.H. Chan School of Public Health, Boston, MA.
Abstract
OBJECTIVE: To determine whether elevated β2-microglobulin (B2M) levels were associated with an increased risk of incident ischemic stroke events among women. METHODS: We performed a nested case-control study among women enrolled in the Nurses' Health Study who provided blood samples between 1989 and 1990 and were free of prior stroke and cancer. We measured B2M levels in 473 ischemic strokes cases confirmed by medical record review and in 473 controls matched 1:1 to the cases on age, race, date of blood collection, menopausal status, postmenopausal hormone use, and smoking status. We analyzed the association between B2M and ischemic stroke using multivariable conditional logistic regression to adjust for traditional stroke risk factors. RESULTS: Median levels of B2M were higher among cases (1.86 mg/L) than controls (1.80 mg/L, p = 0.009, Wilcoxon rank-sum test). Women in the highest B2M quartile had a multivariable-adjusted increased risk of ischemic stroke compared to those in the lowest quartile (odds ratio [OR] 1.56, 95% confidence interval [CI] 1.02-2.39). Results were similar when restricted to those without evidence of chronic kidney disease (estimated glomerular filtration rate ≥60 mL·min-1·1.73 m-2) (OR 1.49, 95% CI 1.08-2.06). In an exploratory analysis, the association between B2M and thrombotic stroke was similar to the overall ischemic stroke results, but no association was observed for embolic stroke risk. CONCLUSION: High levels of B2M were associated with an increased risk of ischemic stroke among women.
OBJECTIVE: To determine whether elevated β2-microglobulin (B2M) levels were associated with an increased risk of incident ischemic stroke events among women. METHODS: We performed a nested case-control study among women enrolled in the Nurses' Health Study who provided blood samples between 1989 and 1990 and were free of prior stroke and cancer. We measured B2M levels in 473 ischemic strokes cases confirmed by medical record review and in 473 controls matched 1:1 to the cases on age, race, date of blood collection, menopausal status, postmenopausal hormone use, and smoking status. We analyzed the association between B2M and ischemic stroke using multivariable conditional logistic regression to adjust for traditional stroke risk factors. RESULTS: Median levels of B2M were higher among cases (1.86 mg/L) than controls (1.80 mg/L, p = 0.009, Wilcoxon rank-sum test). Women in the highest B2M quartile had a multivariable-adjusted increased risk of ischemic stroke compared to those in the lowest quartile (odds ratio [OR] 1.56, 95% confidence interval [CI] 1.02-2.39). Results were similar when restricted to those without evidence of chronic kidney disease (estimated glomerular filtration rate ≥60 mL·min-1·1.73 m-2) (OR 1.49, 95% CI 1.08-2.06). In an exploratory analysis, the association between B2M and thrombotic stroke was similar to the overall ischemic stroke results, but no association was observed for embolic stroke risk. CONCLUSION: High levels of B2M were associated with an increased risk of ischemic stroke among women.
Authors: Brad C Astor; Tariq Shafi; Ron C Hoogeveen; Kunihiro Matsushita; Christie M Ballantyne; Lesley A Inker; Josef Coresh Journal: Am J Kidney Dis Date: 2012-02-04 Impact factor: 8.860
Authors: Amanda G Thrift; Dominique A Cadilhac; Tharshanah Thayabaranathan; George Howard; Virginia J Howard; Peter M Rothwell; Geoffrey A Donnan Journal: Int J Stroke Date: 2014-01 Impact factor: 5.266
Authors: Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort Journal: Lancet Date: 2010-05-17 Impact factor: 79.321
Authors: Stephen P Juraschek; Josef Coresh; Lesley A Inker; Andrew S Levey; Anna Köttgen; Meredith C Foster; Brad C Astor; John H Eckfeldt; Elizabeth Selvin Journal: Clin J Am Soc Nephrol Date: 2013-01-18 Impact factor: 8.237
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Meredith C Foster; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; John Eckfeldt; Stephen P Juraschek; Josef Coresh Journal: Am J Kidney Dis Date: 2013-03-19 Impact factor: 8.860
Authors: Kunihiro Matsushita; Josef Coresh; Yingying Sang; John Chalmers; Caroline Fox; Eliseo Guallar; Tazeen Jafar; Simerjot K Jassal; Gijs W D Landman; Paul Muntner; Paul Roderick; Toshimi Sairenchi; Ben Schöttker; Anoop Shankar; Michael Shlipak; Marcello Tonelli; Jonathan Townend; Arjan van Zuilen; Kazumasa Yamagishi; Kentaro Yamashita; Ron Gansevoort; Mark Sarnak; David G Warnock; Mark Woodward; Johan Ärnlöv Journal: Lancet Diabetes Endocrinol Date: 2015-05-28 Impact factor: 32.069